| Autor: |
Tomishima, Mark, Kirkeby, Agnete, Björklund, Anders, Bloem, Bastiaan R., Brundin, Patrik, Federoff, Howard |
| Předmět: |
|
| Zdroj: |
Journal of Parkinson's Disease; 2021 Supplement 2s, Vol. 11, pS135-S140, 6p |
| Abstrakt: |
After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson's disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
